SOD1 and amyotrophic lateral sclerosis: The recent accelerated approval of toferson by the FDA on the basis of reduction in NfL and the superoxide dismutase 1 (SOD1) protein in patients with ALS resulting from a SOD1 mutation suggests a readiness of some regulatory agencies to accept biomarkers as approvable trial outcomes prior to demonstration of robust clinical benefits [63].